DJIA 16,643.01 -11.76 -0.07%
NASDAQ 4,828.33 15.62 0.32%
S&P 500 1,988.87 1.21 0.06%
market minute promo

VIVUS, Inc. (NASDAQ: VVUS)



company name or ticker

Orexigen: Contrave Wins Another Sales Week - Don't Bank On Impressive Numbers

Vivus Hovers Near 52-Week Lows - Qsymia Sales Not Helping

The 3 Most Disappointing Drug Launches of All Time

Treatments with huge promise don't always pan out the way you'd expect.

This Is a Concern That Amgen Investors Shouldn't Take Lightly

Most investors are focused on the upcoming PDUFA decision for PCSK9 inhibitor Repatha, but this should be a far bigger concern.

Orexigen- Contrave Sales Win The Week But Still Flatter Than Needed

Arena - Belviq Sales Dip Again. We Have Seen The Peak In 2015

Vivus (VVUS) Flagged As Strong On High Volume

Stocks Trading Near Their 52-Week Lows: 4 Hot Picks

VIVUS Inc. (VVUS) in Focus: Stock Jumps 5.4%

VIVUS (VVUS) Is in Oversold Territory: What's Next?

See More Articles...